Cancer Sequencing Breakthrough Creates New Investment Opportunity for Tempus AI
A breakthrough in cancer treatment has led to significant gains for pharmaceutical companies Moderna and Merck. Their personalized cancer vaccines have added over $50 billion to their combined market value.
The success of these vaccines depends on genetic sequencing, which identifies the specific mutations each patient's immune system should target. This diagnostic step is emerging as a potential investment opportunity in its own right.
Tempus AI, a genomic-sequencing firm, is well-positioned to benefit from this trend. As the sequencing partner for Moderna-Merck's vaccine, Tempus has said it will serve if regulators approve the vaccine.
Piper Sandler estimates that the melanoma vaccine could generate at least $50 million in annual sequencing revenue, while BTIG analyst Mark Massaro projects a figure of over $600 million. This estimate assumes expansion into lung, bladder, and kidney cancers.